Nutriband Inc. (NASDAQ:NTRB – Get Free Report) was the target of a large decline in short interest in March. As of March 15th, there was short interest totalling 2,400 shares, a decline of 61.9% from the February 29th total of 6,300 shares. Currently, 0.1% of the shares of the stock are sold short. Based on an average daily trading volume, of 16,100 shares, the days-to-cover ratio is currently 0.1 days.
Nutriband Price Performance
Shares of NTRB traded up $0.47 during trading hours on Thursday, hitting $4.52. The stock had a trading volume of 631,244 shares, compared to its average volume of 34,731. Nutriband has a 52 week low of $1.53 and a 52 week high of $5.93. The stock has a market capitalization of $35.39 million, a price-to-earnings ratio of -6.75 and a beta of 0.72. The company’s fifty day moving average is $2.62 and its two-hundred day moving average is $2.52. The company has a debt-to-equity ratio of 0.37, a current ratio of 2.79 and a quick ratio of 2.54.
Institutional Trading of Nutriband
Large investors have recently added to or reduced their stakes in the company. State Street Corp boosted its holdings in shares of Nutriband by 16.7% in the 3rd quarter. State Street Corp now owns 17,266 shares of the company’s stock worth $62,000 after acquiring an additional 2,466 shares in the last quarter. Vanguard Group Inc. raised its position in Nutriband by 10.4% in the 3rd quarter. Vanguard Group Inc. now owns 85,224 shares of the company’s stock valued at $217,000 after purchasing an additional 8,028 shares during the last quarter. Finally, AlphaQ Advisors LLC acquired a new position in Nutriband in the fourth quarter worth $63,000. 19.70% of the stock is owned by institutional investors.
Nutriband Company Profile
Nutriband Inc develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy.
Featured Stories
- Five stocks we like better than Nutriband
- Comparing and Trading High PE Ratio Stocks
- 3 Value Stocks Too Small For Buffett’s Portfolio
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Foot Locker Builds Up Another Head of Steam; Gains Imminent
- What Is Dividend Yield and How Do You Calculate It?
- Disney Stock Catches 3 Upgrades In a Single Week
Receive News & Ratings for Nutriband Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nutriband and related companies with MarketBeat.com's FREE daily email newsletter.
